Discontinuing semaglutide after weight loss: strategy for weight maintenance and a possible new side effect
We reported the case of a 35-year-old male prescribed oral semaglutide with 22.7 kg weight loss over 120 days. Herein, we describe the clinical course when discontinuing GLP-1 RA therapy, one approach to maintaining weight loss after discontinuation, and a possible new side effect. At day 120, we continued oral semaglutide 7 mg daily, down from 14 mg, for weight maintenance with subsequent weight regain. We re-increased semaglutide to 14 mg/day with weight re-loss within 1 month and weight maintance for a year. We then discontinued semaglutide; weight loss was maintained for 6 months. The patient reported lactose intoleran...
Source: Canadian Journal of Physiology and Pharmacology - April 8, 2024 Category: Drugs & Pharmacology Authors: Nicholas W Carris Shawn Wallace Christopher G DuCoin Rahul Mhaskar Marilyn Stern Brian Bunnell Source Type: research
Discontinuing semaglutide after weight loss: strategy for weight maintenance and a possible new side effect
We reported the case of a 35-year-old male prescribed oral semaglutide with 22.7 kg weight loss over 120 days. Herein, we describe the clinical course when discontinuing GLP-1 RA therapy, one approach to maintaining weight loss after discontinuation, and a possible new side effect. At day 120, we continued oral semaglutide 7 mg daily, down from 14 mg, for weight maintenance with subsequent weight regain. We re-increased semaglutide to 14 mg/day with weight re-loss within 1 month and weight maintance for a year. We then discontinued semaglutide; weight loss was maintained for 6 months. The patient reported lactose intoleran...
Source: Canadian Journal of Physiology and Pharmacology - April 8, 2024 Category: Drugs & Pharmacology Authors: Nicholas W Carris Shawn Wallace Christopher G DuCoin Rahul Mhaskar Marilyn Stern Brian Bunnell Source Type: research
Discontinuing semaglutide after weight loss: strategy for weight maintenance and a possible new side effect
We reported the case of a 35-year-old male prescribed oral semaglutide with 22.7 kg weight loss over 120 days. Herein, we describe the clinical course when discontinuing GLP-1 RA therapy, one approach to maintaining weight loss after discontinuation, and a possible new side effect. At day 120, we continued oral semaglutide 7 mg daily, down from 14 mg, for weight maintenance with subsequent weight regain. We re-increased semaglutide to 14 mg/day with weight re-loss within 1 month and weight maintance for a year. We then discontinued semaglutide; weight loss was maintained for 6 months. The patient reported lactose intoleran...
Source: Canadian Journal of Physiology and Pharmacology - April 8, 2024 Category: Drugs & Pharmacology Authors: Nicholas W Carris Shawn Wallace Christopher G DuCoin Rahul Mhaskar Marilyn Stern Brian Bunnell Source Type: research
Discontinuing semaglutide after weight loss: strategy for weight maintenance and a possible new side effect
We reported the case of a 35-year-old male prescribed oral semaglutide with 22.7 kg weight loss over 120 days. Herein, we describe the clinical course when discontinuing GLP-1 RA therapy, one approach to maintaining weight loss after discontinuation, and a possible new side effect. At day 120, we continued oral semaglutide 7 mg daily, down from 14 mg, for weight maintenance with subsequent weight regain. We re-increased semaglutide to 14 mg/day with weight re-loss within 1 month and weight maintance for a year. We then discontinued semaglutide; weight loss was maintained for 6 months. The patient reported lactose intoleran...
Source: Canadian Journal of Physiology and Pharmacology - April 8, 2024 Category: Drugs & Pharmacology Authors: Nicholas W Carris Shawn Wallace Christopher G DuCoin Rahul Mhaskar Marilyn Stern Brian Bunnell Source Type: research
Discontinuing semaglutide after weight loss: strategy for weight maintenance and a possible new side effect
We reported the case of a 35-year-old male prescribed oral semaglutide with 22.7 kg weight loss over 120 days. Herein, we describe the clinical course when discontinuing GLP-1 RA therapy, one approach to maintaining weight loss after discontinuation, and a possible new side effect. At day 120, we continued oral semaglutide 7 mg daily, down from 14 mg, for weight maintenance with subsequent weight regain. We re-increased semaglutide to 14 mg/day with weight re-loss within 1 month and weight maintance for a year. We then discontinued semaglutide; weight loss was maintained for 6 months. The patient reported lactose intoleran...
Source: Canadian Journal of Physiology and Pharmacology - April 8, 2024 Category: Drugs & Pharmacology Authors: Nicholas W Carris Shawn Wallace Christopher G DuCoin Rahul Mhaskar Marilyn Stern Brian Bunnell Source Type: research
Discontinuing semaglutide after weight loss: strategy for weight maintenance and a possible new side effect
We reported the case of a 35-year-old male prescribed oral semaglutide with 22.7 kg weight loss over 120 days. Herein, we describe the clinical course when discontinuing GLP-1 RA therapy, one approach to maintaining weight loss after discontinuation, and a possible new side effect. At day 120, we continued oral semaglutide 7 mg daily, down from 14 mg, for weight maintenance with subsequent weight regain. We re-increased semaglutide to 14 mg/day with weight re-loss within 1 month and weight maintance for a year. We then discontinued semaglutide; weight loss was maintained for 6 months. The patient reported lactose intoleran...
Source: Canadian Journal of Physiology and Pharmacology - April 8, 2024 Category: Drugs & Pharmacology Authors: Nicholas W Carris Shawn Wallace Christopher G DuCoin Rahul Mhaskar Marilyn Stern Brian Bunnell Source Type: research
Discontinuing semaglutide after weight loss: strategy for weight maintenance and a possible new side effect
We reported the case of a 35-year-old male prescribed oral semaglutide with 22.7 kg weight loss over 120 days. Herein, we describe the clinical course when discontinuing GLP-1 RA therapy, one approach to maintaining weight loss after discontinuation, and a possible new side effect. At day 120, we continued oral semaglutide 7 mg daily, down from 14 mg, for weight maintenance with subsequent weight regain. We re-increased semaglutide to 14 mg/day with weight re-loss within 1 month and weight maintance for a year. We then discontinued semaglutide; weight loss was maintained for 6 months. The patient reported lactose intoleran...
Source: Canadian Journal of Physiology and Pharmacology - April 8, 2024 Category: Drugs & Pharmacology Authors: Nicholas W Carris Shawn Wallace Christopher G DuCoin Rahul Mhaskar Marilyn Stern Brian Bunnell Source Type: research
Prevalence of celiac disease in systemic lupus erythematosus, sjogren syndrome and systemic sclerosis: A systematic review and meta-analysis
Celiac disease (CeD) is an immune-mediated disorder affecting the small bowel, associated with genetic factors and increasing global prevalence. (Source: Digestive and Liver Disease)
Source: Digestive and Liver Disease - April 6, 2024 Category: Gastroenterology Authors: Renato Beas, Euler Altamirano-Farfan, Diego Izquierdo-Veraza, Dalton A. Norwood, Adrian Riva-Moscoso, Ambar Godoy, Eleazar E. Montalvan-Sanchez, Mirian Ramirez, Daniel A. Guifarro, Emily Kitchin, Monika Fischer, Satya Kurada Tags: Meta-Analysis Source Type: research
Nutrition assessment and management in celiac disease.
CeD is the most common immune condition affecting the gastrointestinal tract; it is triggered by gluten and the only available treatment is a strict gluten-free diet (GFD). Therefore, for patients with CeD, adopting a GFD is not a lifestyle choice. The major problem is that a GFD is restrictive, and like all restrictive diets, it has the potential for adverse nutritional outcomes, especially if adopted for a long-term. It is well known that GFD can be nutritionally inadequate and is frequently associated with vitamin and mineral deficiencies; it is, also, associated with excessive sugar and fat intake, particularly when gl...
Source: Gastroenterology - April 6, 2024 Category: Gastroenterology Authors: M Ines Pinto-Sanchez, Jedid-Jah Blom, Peter R. Gibson, David Armstrong Tags: Invited 2024 13th Issue: Celiac Disease Source Type: research
Preservation of the celiac branch of the vagus nerve reduces the incidence of postoperative diarrhea in gastric cancer: a cohort study
To investigate the short-term and long-term outcomes of preserving the celiac branch of the vagus nerve during laparoscopic distal gastrectomy. (Source: World Journal of Surgical Oncology)
Source: World Journal of Surgical Oncology - April 6, 2024 Category: Cancer & Oncology Authors: Hao Guo, WeiFeng Sun, HaiTao Duan, Chi Zhang, MaoHua Wei, Pin Liang, Xiang Hu and Liang Cao Tags: Research Source Type: research
Nutrition Assessment and Management in Celiac Disease
Celiac disease (CeD) is the most common immune condition affecting the gastrointestinal tract; it is triggered by gluten and the only available treatment is a strict gluten-free diet (GFD). Therefore, for patients with CeD, adopting a GFD is not a lifestyle choice. The major problem is that a GFD is restrictive and, like all restrictive diets, it has the potential for adverse nutritional outcomes, especially if adopted for a long term. It is well known that GFD can be nutritionally inadequate and is frequently associated with vitamin and mineral deficiencies; it is also associated with excessive sugar and fat intake, parti...
Source: Gastroenterology - April 6, 2024 Category: Gastroenterology Authors: M. Ines Pinto-Sanchez, Jedid-Jah Blom, Peter R. Gibson, David Armstrong Tags: Invited 2024 13th Issue: Celiac Disease Source Type: research
Coeliac disease: the paradox of diagnosing a food hypersensitivity disorder with autoantibodies
Serum antibodies to the autoantigen transglutaminase 2 (TG2) are increasingly harnessed to diagnose coeliac disease. Diagnostic guidelines for children give recommendation for a no-biopsy-based diagnosis through detection of high amounts of IgA anti-TG2 antibodies in serum with confirmation of positivity in a separate blood sample by characteristic autoantibody-staining of tissue. While measurement of IgA anti-TG2 also is important in the diagnostic workup of adults, the adult guidelines still mandate examination of gut biopsies. This requirement might well change in the future, as might the necessity for confirming autoan...
Source: Gut - April 5, 2024 Category: Gastroenterology Authors: du Pre, M. F., Iversen, R., Sollid, L. M. Tags: GUT Recent advances in basic science, Gut Source Type: research
Duodenal mucosa of untreated celiac disease patients has altered expression of the GAS6 and PROS1 and the negative regulator tyrosine kinase TAM receptors subfamily
Clin Immunol. 2024 Apr 2:110202. doi: 10.1016/j.clim.2024.110202. Online ahead of print.ABSTRACTCeliac disease (CD) is an immune-driven disease characterized by tissue damage in the small intestine of genetically-susceptible individuals. We evaluated here a crucial immune regulatory pathway involving TYRO3, AXL, and MERTK (TAM) receptors and their ligands PROS1 and GAS6 in duodenal biopsies of controls and CD patients. We found increased GAS6 expression associated with downregulation of PROS1 and variable TAM receptors levels in duodenum tissue of CD patients. Interestingly, CD3+ lymphocytes, CD68+, CD11c+ myeloid and epit...
Source: Clinical Immunology - April 4, 2024 Category: Allergy & Immunology Authors: Federico Perez Mar ía Luz Iribarren Cinthia Mariel Olexen Carolina Naym é Ruera Andrea Emilse Errasti Luciana Guzman Laura Garbi Eugenio Antonio Carrera-Silva Fernando Gabriel Chirdo Source Type: research
Duodenal mucosa of untreated celiac disease patients has altered expression of the GAS6 and PROS1 and the negative regulator tyrosine kinase TAM receptors subfamily
Clin Immunol. 2024 Apr 2:110202. doi: 10.1016/j.clim.2024.110202. Online ahead of print.ABSTRACTCeliac disease (CD) is an immune-driven disease characterized by tissue damage in the small intestine of genetically-susceptible individuals. We evaluated here a crucial immune regulatory pathway involving TYRO3, AXL, and MERTK (TAM) receptors and their ligands PROS1 and GAS6 in duodenal biopsies of controls and CD patients. We found increased GAS6 expression associated with downregulation of PROS1 and variable TAM receptors levels in duodenum tissue of CD patients. Interestingly, CD3+ lymphocytes, CD68+, CD11c+ myeloid and epit...
Source: Clinical Immunology - April 4, 2024 Category: Allergy & Immunology Authors: Federico Perez Mar ía Luz Iribarren Cinthia Mariel Olexen Carolina Naym é Ruera Andrea Emilse Errasti Luciana Guzman Laura Garbi Eugenio Antonio Carrera-Silva Fernando Gabriel Chirdo Source Type: research
Duodenal mucosa of untreated celiac disease patients has altered expression of the GAS6 and PROS1 and the negative regulator tyrosine kinase TAM receptors subfamily
Clin Immunol. 2024 Apr 2:110202. doi: 10.1016/j.clim.2024.110202. Online ahead of print.ABSTRACTCeliac disease (CD) is an immune-driven disease characterized by tissue damage in the small intestine of genetically-susceptible individuals. We evaluated here a crucial immune regulatory pathway involving TYRO3, AXL, and MERTK (TAM) receptors and their ligands PROS1 and GAS6 in duodenal biopsies of controls and CD patients. We found increased GAS6 expression associated with downregulation of PROS1 and variable TAM receptors levels in duodenum tissue of CD patients. Interestingly, CD3+ lymphocytes, CD68+, CD11c+ myeloid and epit...
Source: Clinical Immunology - April 4, 2024 Category: Allergy & Immunology Authors: Federico Perez Mar ía Luz Iribarren Cinthia Mariel Olexen Carolina Naym é Ruera Andrea Emilse Errasti Luciana Guzman Laura Garbi Eugenio Antonio Carrera-Silva Fernando Gabriel Chirdo Source Type: research
